{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:16:41Z","timestamp":1791407801048,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013910","name":"Wenzhou Institute of Biomaterials and Engineering","doi-asserted-by":"publisher","award":["WIUCASQD2023014"],"award-info":[{"award-number":["WIUCASQD2023014"]}],"id":[{"id":"10.13039\/501100013910","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013910","name":"Wenzhou Institute of Biomaterials and Engineering","doi-asserted-by":"publisher","award":["WIUCASQD2022027"],"award-info":[{"award-number":["WIUCASQD2022027"]}],"id":[{"id":"10.13039\/501100013910","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.intimp.2026.116980","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:06:54Z","timestamp":1780916814000},"page":"116980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth"],"prefix":"10.1016","volume":"185","author":[{"given":"Chunye","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116980_bb0010","first-page":"656","article-title":"Esophageal cancer global burden profiles, trends, and contributors","volume":"21","author":"Teng","year":"2024","journal-title":"Cancer Biol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.116980_bb0015","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djad020","article-title":"Changes in survival in de novo metastatic cancer in an era of new medicines","volume":"115","author":"Luyendijk","year":"2023","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.intimp.2026.116980_bb0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12032-025-03072-x","article-title":"Cancer metastasis: therapeutic challenges and opportunities","volume":"42","author":"Garemilla","year":"2025","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116980_bb0025","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current Progress in CAR-T cell therapy for hematological malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"issue":"23","key":"10.1016\/j.intimp.2026.116980_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235983","article-title":"Efficacy, Safety, and challenges of CAR T-cells in the treatment of solid tumors","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0035","first-page":"3425291","article-title":"Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a Meta-analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis. Markers"},{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","article-title":"Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?","volume":"18","author":"Vo","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116980_bb0045","first-page":"1","article-title":"Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a Meta-analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis. Markers"},{"issue":"5","key":"10.1016\/j.intimp.2026.116980_bb0050","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.intimp.2026.116980_bb0055","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.116980_bb0060","doi-asserted-by":"crossref","first-page":"89998","DOI":"10.18632\/oncotarget.21286","article-title":"Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer","volume":"8","author":"Kistner","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12935-020-01271-2","article-title":"Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients","volume":"20","author":"Huang","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0070","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s12672-025-02715-9","article-title":"The expression and prognostic value of CCL19 in breast cancer","volume":"16","author":"Ding","year":"2025","journal-title":"Discov. Oncol."},{"issue":"21","key":"10.1016\/j.intimp.2026.116980_bb0075","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.18632\/aging.205184","article-title":"CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers","volume":"15","author":"Gu","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"10.1016\/j.intimp.2026.116980_bb0080","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/bjc.2013.440","article-title":"High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients","volume":"109","author":"Itakura","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.116980_bb0085","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0090","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116980_bb0095","doi-asserted-by":"crossref","first-page":"1570698","DOI":"10.3389\/fimmu.2025.1570698","article-title":"Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116980_bb0100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40259-025-00743-z","article-title":"Oncolytic Virotherapy in solid tumors: a current review","volume":"39","author":"Chen","year":"2025","journal-title":"BioDrugs"},{"issue":"12","key":"10.1016\/j.intimp.2026.116980_bb0105","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nrc948","article-title":"Oncolytic viruses","volume":"2","author":"Antonio Chiocca","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.116980_bb0110","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1348-0421.12753","article-title":"Oncolytic viruses: what to expect from their use in cancer treatment","volume":"64","author":"Terr\u00edvel","year":"2020","journal-title":"Microbiol. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116980_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/v15081645","article-title":"Oncolytic virus engineering and utilizations: Cancer immunotherapy perspective","volume":"15","author":"Muthukutty","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0120","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2026.116980_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0960-0760(92)90180-Q","article-title":"Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor","volume":"43","author":"Wels","year":"1992","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116980_bb0130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.cr.7290191","article-title":"An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy","volume":"13","author":"Zhang","year":"2003","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2026.116980_bb0135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4049\/jimmunol.169.1.424","article-title":"Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis1","volume":"169","author":"Luther","year":"2002","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0140","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4049\/jimmunol.169.1.424","article-title":"Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid Neogenesis1","volume":"169","author":"Luther","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.116980_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00212","article-title":"CCL19 and CCR7 expression, signaling pathways, and adjuvant functions in viral infection and prevention","volume":"7","author":"Yan","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116980_bb0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.intimp.2026.116980_bb0155","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"57","key":"10.1016\/j.intimp.2026.116980_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116980_bb0165","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116980_bb0175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116980_bb0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.116980_bb0185","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s00262-021-02853-3","article-title":"Enhanced anti-tumor efficacy of IL-7\/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models","volume":"70","author":"Goto","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.116980_bb0190","article-title":"Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0195","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116980_bb0200","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2118210","article-title":"CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy","volume":"11","author":"Li","year":"2022","journal-title":"Oncoimmunology"}],"updated-by":[{"DOI":"10.1016\/j.intimp.2026.117021","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000}},{"DOI":"10.1016\/j.intimp.2026.117021","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600826X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600826X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:08:53Z","timestamp":1786651733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692600826X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S156757692600826X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116980","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116980"}}